The improvement of hepatic insulin sensitivity by the cannabinoid receptor 1 (CB1R) antagonist rimonabant (RIM) has been recently been reported to be due to upregulation of adiponectin. Several studies demonstrated that improvement in insulin clearance accompanies the enhancement of hepatic insulin sensitivity. However, the effects of RIM on hepatic insulin clearance (HIC) have not been fully explored. The aim of this study was to explore the molecular mechanism(s) by which RIM affects HIC, specifically to determine whether upregulation of liver adiponectin receptors (ADRs) and other key genes regulated by adiponectin mediate the effects. To induce insulin resistance in skeletal muscle and liver, dogs were fed a hypercaloric high-fat diet (HFD) for 6 wk. Thereafter, while still maintained on a HFD, animals received RIM (HFDϩRIM; n ϭ 11) or placebo (HFDϩPL; n ϭ 9) for an additional 16 wk. HIC, calculated as the metabolic clearance rate (MCR), was estimated from the euglycemichyperinsulinemic clamp. The HFDϩPL group showed a decrease in MCR; in contrast, the HFDϩRIM group increased MCR. Consistently, the expression of genes involved in HIC, CEACAM-1 and IDE, as well as gene expression of liver ADRs, were increased in the HFDϩRIM group, but not in the HFDϩPL group. We also found a positive correlation between CEACAM-1 and the insulin-degrading enzyme IDE with ADRs. Interestingly, expression of liver genes regulated by adiponectin and involved in lipid oxidation were increased in the HFDϩRIM group. We conclude that in fat-fed dogs RIM enhances HIC, which appears to be linked to an upregulation of the adiponectin pathway. CB1R antagonist; dogs; insulin resistance; insulin clearance; liver THE METABOLIC SYNDROME is a cluster of abnormalities [abdominal obesity, dyslipidemia, hypertension, and nonalcoholic steatohepatitis (NASH)] that are related to insulin resistance and subsequent development of type 2 diabetes. The endocannabinoid system has garnered a great deal of attention as a potential therapeutic target in combating obesity as well as its associated metabolic abnormalities. Compared with their corresponding controls, patients with obesity and type 2 diabetes exhibit higher levels of endocannabinoids in the visceral fat and serum, respectively (32). Chronic treatment with the cannabinoid (CB) receptor (CB1R) antagonist rimonabant (RIM) leads to weight loss and improved insulin sensitivity in obese rodents (15, 43), canines (44), and humans (51). Moreover, several studies have recently shown that RIM has beneficial effects on the liver (14, 15). RIM has been shown to reverse steatohepatitis and related features of metabolic syndrome (15, 49). Thus, although the commercial cannabinoid receptor antagonist RIM has been withdrawn from the market, it remains important to study the cannabinoid receptor system if additional non-centrally-acting antagonists become available (50). Also, the tremendous increase in cannabinoid intake in the U.S. and elsewhere (10) supports studies of the effects of these agonists and their antagonists.
THE METABOLIC SYNDROME is a cluster of abnormalities [abdominal obesity, dyslipidemia, hypertension, and nonalcoholic steatohepatitis (NASH)] that are related to insulin resistance and subsequent development of type 2 diabetes. The endocannabinoid system has garnered a great deal of attention as a potential therapeutic target in combating obesity as well as its associated metabolic abnormalities. Compared with their corresponding controls, patients with obesity and type 2 diabetes exhibit higher levels of endocannabinoids in the visceral fat and serum, respectively (32) . Chronic treatment with the cannabinoid (CB) receptor (CB1R) antagonist rimonabant (RIM) leads to weight loss and improved insulin sensitivity in obese rodents (15, 43) , canines (44) , and humans (51) . Moreover, several studies have recently shown that RIM has beneficial effects on the liver (14, 15) . RIM has been shown to reverse steatohepatitis and related features of metabolic syndrome (15, 49) . Thus, although the commercial cannabinoid receptor antagonist RIM has been withdrawn from the market, it remains important to study the cannabinoid receptor system if additional non-centrally-acting antagonists become available (50) . Also, the tremendous increase in cannabinoid intake in the U.S. and elsewhere (10) supports studies of the effects of these agonists and their antagonists.
In abdominally obese patients with atherogenic dyslipidemia, the CB1R antagonist RIM improves multiple cardiometabolic risk markers and induces significant reductions in both intra-abdominal and liver fat (12) , likely due to an increase and upregulation of adiponectin (2, 27, 50) . Adiponectin is produced in adipose tissues and released into the circulation and is directly linked to insulin sensitivity (22, 47) ; specifically, euglycemic clamp studies performed in obese humans demonstrate that plasma adiponectin levels are significantly correlated with insulin sensitivity (7) . In addition, RIM treatment has been shown to increase adiponectin mRNA expression in adipose tissue of obese fa/fa rats, diet-induced obese mice (18) , and cultured adipocytes (2) .
High-fat feeding in canines results in increased fat accumulation in both the visceral (VIS) and subcutaneous (SQ) fat depots and impairs whole body and hepatic insulin sensitivity (27, 44) , whereas RIM treatment decreases body weight and adiposity independently of changes in food intake (44) .
Insulin clearance has been shown to decrease in individuals with type 2 diabetes (29) and obesity (39) , and reduction in insulin clearance appears to precede insulin resistance and hyperinsulinemia (25) . In the canine model, Ader et al. (1) showed a positive correlation between hepatic insulin clearance and insulin sensitivity as measured by the euglycemichyperinsulinemic clamp.
Adiponectin is known to antagonize excess lipid storage and protect against inflammation and steatosis in the liver (6) . Consistently, plasma adiponectin levels were lower and adiponectin receptor 2 (ADR2) staining weaker in obese, insulinresistant subjects with NASH (23) . Interestingly, the carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM-1) has been linked not only to insulin clearance but also to liver fat accumulation and NASH (34) . In fact, null mutation of CEACAM-1 (Cc1 Ϫ/Ϫ ) leads to impairment of insulin clearance and hyperinsulinemia (41) and induces the transcription of lipogenic enzymes in liver, resulting in increased hepatic lipid production and output (9, 36) .
Many of the peripheral effects of RIM have been studied, and the beneficial metabolic effects have been associated with an upregulation of adiponectin; however, the effects of RIM on hepatic insulin clearance are not well understood. The aim of this study was to explore the molecular mechanism(s) by which RIM affects hepatic insulin clearance in fat-fed dogs and specifically to determine whether this is associated with upregulation of liver ADRs and other key genes regulated by adiponectin.
MATERIALS AND METHODS
Animals and diet. Briefly, twenty male mongrel dogs (29 Ϯ 0.9 kg body wt) were housed in the vivarium of the Keck School of Medicine, University of Southern California (USC) under controlled kennel conditions (12:12-h light-dark cycle). Experimental protocols were approved by the Institutional Animal Care and Use Committee of USC. Data depicting metabolic changes were previously published (44) .
Upon arrival, dogs underwent a period of acclimation for 3 wk, during which they were fed a standard diet. After 3 wk, animals were fed a hypercaloric high-fat diet (HFD), which consisted of ϳ5,527 kcal/day (28% carbohydrates, 53% lipids, and 19% proteins), representing an ϳ20% increase in calories from fat. Previous studies had demonstrated that 6 wk of fat feeding promotes a consistent increase of fat in the abdominal trunk and subcutaneous depot, rendering dogs insulin resistant (24) . Thus, the HFD was maintained for a minimum period of 6 wk (average: 9 Ϯ 2 wk) prior to RIM treatment.
Treatment. After the initial establishment of insulin resistance with 6 wk of HFD, dogs were randomly assigned to two groups while being maintained on the HFD for an additional 16 wk. One group received RIM, HFDϩRIM (n ϭ 11); the other group received placebo, HFDϩPL (n ϭ 9). Hence, in total, each animal was on 22 wk of HFD by the end of the study. RIM (Sanofi-Aventis, Paris, France) was encapsulated (AMC Pharmacy, Burbank, CA) and administered orally at 1.25 mg·kg Ϫ1 ·day Ϫ1 . Placebo-treated animals received inert capsules (44) .
In vivo metabolic assessment and tissue biopsies. Data about food intake, body weight, and some biochemical parameters have been published elsewhere (27, 44) . All animals underwent metabolic assessments in random order at three time periods: prior to fat feeding (week 6, or Prefat), after 6 wk of an initial fat feeding period to induce insulin resistance (week 0, or HFD), and after an additional 16 wk of fat feeding concomitant with either placebo (HFDϩPL) or rimonabant (HFDϩRIM). At each of the three designated time points (Prefat, HFD, HFDϩPL, and HFDϩRIM), biopsies were taken from SQ and VIS fat depots as well as liver, where we excised ϳ500 mg of tissue and placed it in RNAse-free conditions. Biopsies were conducted rapidly under general inhalant anesthesia, and tissues were frozen in liquid nitrogen. All studies and plasma measurements were performed after an overnight fast (ϳ12 h).
Insulin sensitivity was assessed by the euglycemic-hyperinsulinemic clamp (27) . Hepatic insulin clearance was measured as the metabolic insulin clearance (MCR), estimated as the ratio of insulin infusion rate to steady-state plasma insulin levels during the euglycemic-hyperinsulinemic clamp (27) .
Total RNA isolation and real-time PCR. RNA was extracted from biopsied tissues using the Tri Reagent Kit (Molecular Research Center, Cincinnati, OH). First-strand cDNA was synthesized, according to the manufacturer's protocol, from 1 g of total RNA obtained from the liver and adipose tissue biopsies using Superscript II (Invitrogen, Carlsbad, CA). RT-PCR was performed using a Light-Cycler 4.8 instrument (Roche Applied Science, Indianapolis, IN). The cDNA was amplified using the "universal probe system" on a Roche microplate with a final volume of 10 l reaction mix containing 2.5 l, 100-fold diluted cDNA, 7 l LightCycler TaqMan Master Mix buffer (Roche Probes Master kit, Roche Applied Science), 1 M specific forward-reverse primers, and 0.5 l specific universal probes. Primers and universal probes are shown in Table 3 . Quantification of 18S rRNA was used for sample normalization using a SYBR Green I kit. PCR was performed according to the manufacturer's protocol (Roche Applied Science). The specificity of amplification was determined by melting curve analysis. The results were analyzed by relative quantification, ⌬⌬C T method.
Western blot. Protein lysates were prepared by homogenizing 100 mg of liver tissue in Cell Lysis Buffer (Cell Signaling Technology, Danvers, MA) supplemented with protease inhibitor cocktail and phosphatase inhibitor cocktail (Sigma-Aldrich, St. Louis, MO). The homogenate was centrifuged at 13,000 rpm for 30 min at 4°C. The supernatant was collected and total protein concentration in the supernatant determined using a BCA protein assay kit (Thermo Fischer Scientific, Canoga Park, CA). Equal amounts of proteins were separated on a 10% Mini-Protean TGX precast SDS-PAGE gel (Bio-Rad Laboratories, Irvine, CA) by electrophoresis, transferred onto a nitrocellulose membrane (Bio-Rad Laboratories) using a TransBlot SD Semi Dry Transfer Cell (Bio-Rad Laboratories). For AMPK and p-AMPK as well as ␤-actin (Cell Signaling Technology, Danvers, MA) the membranes were blocked with 5% nonfat dry milk in 1ϫ Tris-buffered saline with Tween 20 (TBST) for 1 h at room temperature and then incubated overnight at 4°C with 1:500 diluted polyclonal primary antibodies. For CB1 (Abcam, Cambridge, MA), the membranes were blocked for 2 h at room temperature in 5% BSA in TBST and then incubated overnight at 4°C with 1:200 diluted polyclonal primary antibodies. For CEACAM-1 and p-CEACAM-1 (kindly provided by Dr. Sonia Najjar), the membranes were blocked overnight in Na-orthovanadate, 3% BSA, and phosphate-buffered saline with the detergent Tween 20 (PBST) and then incubated overnight at 4°C with 1:500 diluted polyclonal primary antibodies. The membranes were then washed and incubated with 1:5,000 diluted Alexa fluor 680 anti-rabbit secondary antibody (Life Technology) for 1 h at room temperature. Signals were detected and quantitated with the Odyssey Infrared Imaging System (Li-COR, Lincoln, NE) and accompanying Li-COR software. The band densities of AMPK, p-AMPK, CEACAM-1, p-CEACAM-1, and CB1R were normalized to that of ␤-actin.
Liver histology and triglyceride measurement. Livers were fixed with 10% neutral formalin, embedded in paraffin, cut with a microtome in 5-m-thick paraffin sections, placed on glass slides, and stained with hematoxylin and eosin (H&E). We also used Oil Red O (Sigma-Aldrich) staining to quantify liver lipid content. Liver sections were flash-frozen and embedded in frozen medium (Optimal Cutting Temperature Compound, Ted Pella). The 5-m sections were cut and fixed to microscope slides, allowed to air-dry overnight at room temperature, and stained with fresh Oil Red O for 15 min, rinsed in water, and then counterstained with hematoxylin. Ten randomly selected sections were photographed and examined. Liver fat accumulation was graded based on semiquantitative estimation of the percentage of lipid-laden hepatocytes. Triglyceride (TG) content in liver tissue was determined as previously described. Briefly, total lipids from 60 mg of liver tissues were extracted with 30 vol (vol/wt) of acidified chloroform-methanol (2:1). After removal of the upper phase and conversion of the infranatant to a uniform phase with methanol, total TG content was determined enzymatically with a commercially available assay (Sigma-Aldrich) using triolein as the calibration standard (48) .
Biochemical parameters. Glucose was measured using a YSI 2300 analyzer (Yellow Springs Instruments, Yellow Springs, OH). Insulin from plasma samples was determined by ELISA (Linco Research, St. Charles, MO), using dog plasma for standards (27) . Free fatty acids were measured utilizing a colorimetric assay based on the acylation of coenzyme A from Wako (NEFA C; Wako Pure Chemical Industries, Richmond, VA). Canine adiponectin, leptin, and glucagon concentrations were measured using ELISA kits (Millipore, Temecula, CA). Serum alanine transaminase (ALT) and aspartate transaminase (AST) levels were measured by Quest Laboratory (Irvine, CA) only in prefat, HFDϩPL, and HFDϩRIM periods. Plasma IL-6 and TNF␣ were measured using canine ELISA kits (R&D Systems, Minneapolis, MN).
Statistical analyses. All experimental data presented in this study are expressed as means Ϯ SE unless otherwise indicated. For the comparison of changes from baseline (HFD) to week 16 (W16) between the two groups (HFDϩPL vs. HFDϩRIM), two-way ANOVA adjusted by baseline was used. When the data were not normally distributed, nonparametric median score one-way analysis was used. Changes from prefat to HFD before randomization were compared with "zero" (null hypothesis) using the Wilcoxon signed ranked test. Spearman correlation was used to test the associations between CEACAM-1, the insulin-degrading enzyme IDE, ADRs, MCR, and plasma adiponectin. As multiple statistical tests were performed simultaneously on a single data set, the Bonferroni correction, as a conservative method, was applied to adjust the P values [critical P value (␣) was divided by the number of comparisons made]. All statistical analyses were performed with SAS v. 9.2 (SAS Institute, Cary, NC).
RESULTS
Metabolic profile: effects of treatments. The effects of treatments are presented in Table. 1. Animals in HFDϩPL (W16) group increased their body weight by ϳ2 kg (HFD: 31.83 Ϯ 1.45 vs. HFDϩPL: 33.90 Ϯ 1.86), whereas HFDϩRIM (W16)-treated dogs lost ϳ0.90 kg compared with HFD (HFD: 31.70 Ϯ 1.34 vs. HFDϩRIM: 30.80 Ϯ 1.14; P Ͻ 0.0002). At the end of 16 wk of treatment, fasting glucose, insulin, and FFA remained unchanged between the groups. Glucagon decreased by 13 pg/ml in the HFDϩPL group compared with the RIM group. However, the statistical test showed a nonsignificant difference when taking account of the multiplicity of tests using a Bonferroni adjustment. There was no change in fasting adiponectin levels by HFD, whereas adiponectin levels increased by 80% with RIM treatment (P Ͻ 0.0002) (27) . HFD increased leptin levels in HFDϩPL compared with the HFDϩRIM group (P Ͻ 0.029). At the end of 16 wk of treatment, ALT and AST remained unchanged ( Table 1) .
Effects of 6 wk of fat feeding. The effects of fat feeding is presented in Table 2 . As expected, fat feeding increased body weight by ϳ2 kg (P Ͻ 0.0001), insulin by 55% (P Ͻ 0.0006), and leptin by 77% (P Ͻ 0.0001). Glucose, glucagon, FFA, and adiponectin remained unchanged by 6 wk of fat feeding.
In Median ϭ 1.00
Values are means Ϯ SE; n ϭ 20. RIM, rimonabant; ALT, alanine transaminase; AST, aspartate transaminase; W, week. No significant difference on baseline. (a) Two-way ANOVA adjusted by baseline. (b) Nonparametric median score test. *Only a trend is observed, taking account of the multiplicity of tests, using a Bonferroni adjustment (9 tests) the critical P value would be 0.0055 (0.05/9). **Missing data on W0, W6 is taken. group (HFD: 271 Ϯ 36 pM vs. HFDϩRIM: 279 Ϯ 13 pM) (P Ͻ 0.05). Hence, steady-state plasma insulin was decreased with RIM treatment, consistent with increased insulin clearance. To demonstrate changes in HIC at the molecular level, we studied two genes involved in hepatic insulin clearance, CEACAM-1 and IDE (Fig. 1, B and C) . CEACAM-1 gene expression did not change from Prefat to HFD period; however, CEACAM-1 gene expression decreased after 22 wk of fat feeding (P Ͻ 0.05). Interestingly, RIM treatment increased expression of this gene compared with the HFDϩPL period. Since insulin induces phosphorylation of CEACAM-1, which, in turn, facilitates its endocytosis and degradation (40), we measured phosphorylated the CEACAM-1 ratio to total CEACAM-1 protein expression. Similar to the gene expression data, we showed that the ratio of p-CEACAM-1 to total CEACAM-1 decreased significantly compared with the Prefat period (P Ͻ 0.05), RIM increased the expression of p-CEACAM-1 compared with the PL group (Fig. 1B) . IDE expression decreased significantly by 27% during that period (P Ͻ 0.05). IDE decreased by 65% with additional fat feeding in the HFDϩPL group; however, additional fat feeding with RIM treatment prevented decrements in IDE. Hence, for the first time we demonstrate that RIM increases the expression of enzymes associated with liver insulin degradation.
Adiponectin gene expression in the fat depot, liver ADRs, and CB1R gene and protein expressions. Six weeks of fat feeding did not modify adiponectin gene expression in either SQ or VIS fat depots. However, RIM treatment increased adiponectin gene expression in the SQ by 67%, (P Ͻ 0.05) and threefold, (P Ͻ 0.001) in the VIS fat depots compared with pretreatment or HFD period ( Fig. 2A) . To study the downstream effects of adiponectin, we evaluated mRNA levels of ADR1 and ADR2 in the liver. ADR1 decreased significantly following prolonged fat feeding in the HFDϩPL in contrast to the HFDϩRIM group (P Ͻ 0.05), where ADR1 was increased 2.28-fold. Similarly, ADR2 showed a tendency to decrease in Values are means Ϯ SE; n ϭ 20. *Signed rank test the HFDϩPL group (P Ͻ 0.07) compared with the HFD period, whereas RIM treatment significantly increased it 1.86-fold (P Ͻ 0.05; Fig. 2B ). Gene expression of liver CB1R increased in the HFD group fourfold compared with the Prefat group, (P Ͻ 0.01). There was no significant difference in CB1R expression between HFDϩPL and HFDϩRIM compared with the HFD. However, there was a tendency for CB1R protein expression to be increased in the HFDϩPL group (P ϭ 0.09) compared with the Prefat period. CB1R protein expression of liver CB1R remained unchanged between HFDϩPL and HFDϩRIM (Fig. 2C) .
Insulin clearance correlation with adiponectin. Both types of ADRs in the liver were strongly correlated with CEACAM-1 (ADR1 and CEACAM-1, R ϭ 0.69, P Ͻ 0.001; ADR2 and CEACAM-1, R ϭ 0.68, P Ͻ0.01; Fig. 3A) . Likewise, ADR1 showed a positive correlation with IDE (R ϭ 0.71, P Ͻ 0.005), and a similar tendency was observed for ADR2 and IDE (R ϭ 0.40, P ϭ 0.08; Fig. 3B ). MCR and plasma adiponectin showed a tendency to be correlated (R ϭ 0.43, P ϭ 0.052). These findings, together suggest that the increased HIC by RIM is linked to an upregulation of the adiponectin.
Genes regulated by adiponectin: fatty acid oxidation, thermogenesis, and inflammation gene expressions. ADR1 is strongly related to the activation of the adenosine monophosphate-activated protein kinase (AMPK) pathway. ADR2 is involved in the activation of the peroxisome proliferatoractivated receptor-␣ (PPAR␣), which stimulates energy dissipation by increasing fatty acid oxidation (20) . We quantified phosphorylated vs. total AMPK protein ratio by Western blot analysis. The p-AMPK to total AMPK ratio decreased by 52% (P Ͻ 0.05) in HFDϩPL compared with Prefat, whereas RIM treatment partially improved (by 32%) this ratio (Fig. 4A) , indicating an activation of the ADR1-AMPK pathway.
RIM increased hepatic PPAR␣ eightfold compared with the HFDϩPL group (P Ͻ0.005). We also measured hepatic genes downstream of PPAR␣ that are involved in fatty acid oxidation. RIM increased the expression of carnitine palmitoyltransferase-1 (CPT1) sevenfold compared with the HFDϩPL group (P Ͻ 0.001; Fig. 4B ). As mentioned above, HFDϩRIM-treated dogs had lower body weight than placebo-treated dogs despite the same amount of food intake, which suggests that RIM is improving glucose homeostasis by augmenting energy expenditure. Therefore, we determined whether the levels of the uncoupling proteins (UCPs) were changed by RIM treatment. UCPs are the inner mitochondrial membrane ion carriers that dissipate the proton gradient to generate energy during oxidative phosphorylation (45) . HFD led to a significant reduction in mRNA levels of UCP2 compared with the Prefat period (Ϫ45%, P Ͻ 0.01). This reduction in UCP2 expression was more pronounced in the HFDϩPL group (Ϫ71%, P Ͻ 0.05) than in the HFD group. UCP2 expression remained unchanged compared with the Prefat period in the RIMϩPL group. We found UCP3 to have a similar trend: UCP3 decreased significantly in HFDϩPL (Ϫ65%; P Ͻ 0.05), whereas UCP3 remained unchanged compared with the Prefat period (Fig. 4B) . These data demonstrated that RIM restored UCP2 and -3 expression to pretreatment levels. We also studied three key enzymes involved in mitochondrial fatty acid oxidation (short-, medium-, and long-chain acyl-CoA dehydrogenase, SCAD, MCAD, LCAD). Twenty-two weeks of fat feeding decreased SCAD expression by 69% (P Ͻ 0.005) in the HFDϩPL group, whereas RIM treatment increased SCAD by 40% (P Ͻ 0.01) compared with the Prefat period. A similar trend was observed for MCAD and LCAD (Fig. 4C) . These experiments suggest that fatty acid oxidation as well as thermogenesis increased by RIM treatment, which is consistent with reductions in body weight following RIM treatment without changes in food intake.
We also measured expression of two major proinflammatory cytokines, IL-6 and TNF␣, in the liver (Fig. 5A ). IL-6 expression was significantly increased by fat feeding (2-fold, P Ͻ 0.005). Further exposure to fat feeding did not increase IL-6 gene expression in the HFDϩPL group. However, RIM treatment significantly decreased IL-6 expression compared with the Prefat condition (3-fold, P Ͻ 0.005). A similar trend was observed for TNF␣ gene expression. TNF␣ increased fourfold by 6 wk of fat feeding (P Ͻ 0.001). TNF␣ returned back to the Prefat period in the HFDϩPL group, while RIM treatment significantly decreased TNF␣ expression compared with the Prefat condition (5-fold, P Ͻ 0.001). These data suggest that RIM may decrease liver inflammation. In addition, measurement of IL-6 and TNF␣ in the plasma (Fig. 5B) found a significant increase in IL-6 and TNF␣ levels with HFD compared with the Prefat period (P Ͻ 0.001). Plasma IL-6 had a tendency to be decreased by HFDϩRIM compared with the HFDϩRIM group (P ϭ 0.052), however, RIM decreased TNF␣ significantly compared with the HFDϩPL group (P Ͻ 0.05). Taken together, these data suggest that RIM may decrease liver inflammation. Liver histopathology and hepatic TG content. As revealed by H&E and Oil Red O staining, dogs fed a HFD for 22 wk (HFDϩPL) had a mild accumulation of fat in the liver, which was reversed by RIM treatment (Fig. 6, A and B) . Although liver TG content was not significantly different between the groups, we observed the same trend as we did in the histology measurements (Fig. 6C) .
Lipogenic enzyme gene expressions. Fatty acid synthase (FAS) tended to decrease after RIM treatment (P Ͻ 0.08). Interestingly sterol regulatory element-binding transcription factor 1c (SREBP1c) decreased significantly by RIM treatment (P Ͻ 0.01; Fig. 7 ), further suggesting that RIM treatment may decrease lipogenesis.
DISCUSSION
Clinical and animal studies have previously demonstrated that RIM reduces body weight, improves symptoms associated with the metabolic syndrome, and decreases cardiovascular risk factors (11, 43, 44) . Several studies have demonstrated beneficial effects of RIM on the liver (15, 53), suggestive of an important role for adiponectin, as demonstrated by the fact that RIM increases plasma adiponectin in animals and humans (15, 27, 50) . Our data suggest that the endocannabinoid system plays a fundamental role in the regulation of body weight. More recently, promising new pharmacology suggests that non-brain-penetrating CB1R antagonists improve insulin sensitivity (8, 50) .
The liver plays an important role in hyperinsulinemic compensation by modulating hepatic insulin clearance. We (25) have previously shown that in our obese, insulin-resistant dogs, HIC reduces significantly to maintain hyperinsulinemia. In the present study, we explored the mechanisms by which RIM enhances HIC.
We (27) have previously demonstrated that plasma adiponectin levels doubled with RIM treatment. Consistent with these findings, adiponectin gene expression increased in the SQ and VIS fat depots by RIM treatment. According to the "portal theory", the visceral adipose tissue directly releases its metabolites into the portal vein which are then delivered to the liver (5, 19) . Given that adiponectin is an insulin sensitizer (3, 47) and is directly delivered to the liver via the portal circulation, it is plausible that adiponectin secreted by the VIS fat due to RIM treatment improved the observed increase in hepatic insulin sensitivity. Thus, we measured ADR1 and ADR2 gene expressions in the liver, both receptors demonstrating decreases after prolonged fat diet exposure in the HFDϩPL group. Consistent with our data, it has been demonstrated that expression levels of ADR1 and ADR2 were decreased by ϳ65 or 55%, respectively, in the livers of db/db mice compared with wild-type mice (21) . Interestingly, despite continued fat feeding, RIM increased the expressions of ADR1 and ADR2 compared with the HFDϩPL group, suggesting a direct effect of RIM on ADRs in the liver. Moreover, CB1R expression increased with 6 wk of fat feeding with no further change in the RIM group. We also measured CB1R protein expression in Prefat, HFDϩPL, and HFDϩRIM groups. Although there was no significant change between the groups, HFDϩPL showed a tendency to increase compared with the Prefat period. We did not observe a difference in CB1R protein expression between HFDϩPL and HFDϩRIM. These results suggest that the beneficial effects of RIM on the liver might be mediated primarily via the adiponectin pathway.
In the present study, we estimated HIC using MCR, a surrogate method based on the euglycemic-hyperinsulinemic clamp, while controlling insulin infusion rates (26, 27) . We demonstrated that 6 wk of fat feeding as well as prolonged fat feeding (22 wk in HFDϩPL) decreased MCR. Interestingly, we demonstrated that the MCR increased in the HFDϩRIM compared with the HFDϩPL group. There was a tendency for fasting plasma insulin to be decreased in RIM compared with the HFDϩPL group. In addition, plasma insulin concentration during the clamp steady state decreased in the HFDϩRIM group, further suggestive of an increase in insulin clearance following RIM treatment. We have previously reported no changes in plasma insulin during high-glucose challenge in dogs that received RIM treatment; however, we did observe a tendency for lower plasma C-peptide concentrations (52). The MCR findings are supported by a 2.5-fold increase in the expressions of genes involved in insulin clearance, namely, CEACAM-1 and IDE. CEACAM-1 is an important factor involved in hepatic receptor-mediated endocytosis and degradation of insulin (41) . Loss of CEACAM-1 causes insulin resistance, hepatic steatosis, and inflammation (35) . We found that 22 wk of fat feeding decreased the gene expression of CEACAM-1. Similarly, the p-CEACAM-1 ratio to total CEACAM-1 decreased in the HFDϩPL group compared with the Prefat period. Interestingly, RIM increased the gene expression of CEACAM-1 by 2.5 times and p-CECAM-1/ CEACAM-1 protein expression by 40% compared with HFDϩPL. IDE showed similar results. We also found a positive correlation between gene expression of CEACAM-1 and (31) .
We further studied genes regulated by adioponectin. Adiponectin when bound to ADR1 and ADR2 activates two different pathways in the liver. ADR1 leads to phosphorylation activation of AMPK, which in turn stimulates fatty acid oxidation, while ADR2 is involved in the activation of PPAR␣2, which propagates energy dissipation (20) . Also, studies by Yamauchi and colleagues (54, 55) indicate that the insulinsensitizing effect of adiponectin on the liver is mediated by an increase in hepatic fatty acid oxidation. Hence, we studied the factors regulating fatty acid oxidation and energy dissipation in the liver. We found that, with 22 wk of fat feeding in the HFDϩPL group, AMPK phosphorylation decreased significantly; however, RIM treatment partially restored AMPK activation. Our finding is consistent with Heiker et al. (16) , who showed that increased serum adiponectin results in an increase in AMPK activation via ADRs. Our results are also consistent with glucagon-mediated activation of AMPK in the liver (4, 28) . We demonstrated that fasting glucagon had a tendency to be decreased in the HFDϩPL compared with the HFDϩRIM group, which is cosnsistent with the results obtained for AMPK activation.
PPAR␣ is the transcription factor that regulates the expression of several genes involved in mitochondrial, peroxisomal, and microsomal fatty acid oxidation enzymes in the liver (17) .
We found an eightfold increase in PPAR␣ with RIM treatment compared with Prefat, HFD, and HFDϩPL groups. CPT1 is a key regulatory enzyme in the mitochondria, responsible for transferring fatty acids from the cytosol to the mitochondria before ␤-oxidation (46). We found a sevenfold increase in CPT1 gene expression, indicating an increased flux of FFA to the mitochondria with RIM treatment. These results are consistent with a recent study showing that RIM treatment increased fatty acid oxidation via upregulation of CPT1 and PPAR␣ only in adiponectin ϩ/ϩ and not in adiponectin Ϫ/Ϫ mice (49). UCPs are the inner mitochondrial membrane ions carriers that dissipate the proton gradient to generate energy during oxidative phosphorylation (45). Zhou et al. showed that adiponectin treatment restores mitochondrial function, depletes lipid accumulation, and upregulates the mRNA and protein expression of UCP2 in the liver of adiponectin KO mice. In addition, they showed that hepatoprotective functions of adiponectin were significantly attenuated in UCP2 knockout mice (56) . In the present study, we demonstrated that UCP2 and UCP3 gene expressions were decreased by 22 wk of fat feeding in the HFDϩPL group. We showed for the first time that RIM treatment restored the expression of these two genes to the pretreatment period. We also evaluated the mRNA expressions of SCAD, MCAD, and LCAD as markers of enzymes of mitochondrial ␤-oxidation. Fat feeding significantly decreased SCAD in the HFDϩPL group compared with the Prefat period. We observed similar trends in the expressions of MCAD and LCAD with fat feeding. RIM, however, restored SCAD, MCAD, and LCAD levels to those of the Prefat period. Thus, our results are consistent with other studies (13, 49) showing that RIM increased fatty acid oxidation in a fat-fed model of insulin resistance. The anti-inflammatory property of adiponectin has been extensively studied in the past decade (38) . Human and animal studies have demonstrated that plasma adiponectin levels are inversely correlated with those of plasma proinflammatory cytokines (37, 38) . In our study, we found that gene expression of hepatic IL-6 and TNF␣ as well as plasma concentrations increased significantly after 6 wk of fat feeding. Based on our results, it appears that high-fat feeding causes an initial robust inflammatory response in the liver that is only partially sustained with further chronic high-fat feeding, suggesting an adaptation of the hepatic inflammatory cytokines with chronic fat feeding in the HFDϩPL group. However, we demonstrated that plasma cytokine levels remained elevated with longer fat feeding. Interestingly, RIM treatment decreased gene expression as well as plasma concentrations of these cytokines to those found in HFD group.
We also found mild fat accumulation and TG accumulation in the liver after fat feeding. This is in contrast to the findings in the rodent model and in humans, where fatty liver is a commonality (30, 42) . Interestingly, histology of the liver showed that RIM reversed the diet-induced mild fat accumulation in the liver to the Prefat period. In addition, we found that factors involved in lipid accumulation and de novo lipogenesis, namely SREBP1c, decreased significantly by RIM treatment. FAS gene expression demonstrated the same tendency. These results are consistent with other studies showing that reversal of HFD-induced hepatic steatosis and fibrosis by RIM requires adiponectin (49) . Although this study demonstrated that some hepatoprotective effects of RIM such as improvement of hepatic steatosis and fatty acid oxidation are adiponectin dependent, other metabolic effects, such as decreased improvement of hepatic insulin resistance by RIM, are independent of adiponectin. By contrast, a study in dietinduced obese mice showed that RIM treatment decreased hepatic insulin resistance via an adiponectin-dependent mechanism (33) . There are a number of factors that may account for the variability in adiponectin dependence, such as the animal model and the duration of the treatment. In our study, we did not show a direct effect of adiponectin improving insulin sensitivity. However, we demonstrated that ADRs decreased by HFD and improved by RIM treatment. We also showed a strong correlation between insulin clearance and ADRs. Hence, some effects of CB1 antagonist such as an increase of insulin clearance, fatty acid oxidation, and decrease of inflammation markers and lipid in the liver may be mediated by adiponectin. Further studies are needed to clarify the direct effect of adiponectin on insulin sensitivity.
In conclusion, the findings of the present study demonstrate that RIM increases HIC, most likely by targeting CEACAM-1 and IDE, which in turn is associated with upregulation of ADRs. We also confirmed the hepatoprotective effect of RIM, namely upregulation of genes linked to fatty acid oxidation, improved inflammation, and fat accumulation, in the liver, mainly via upregulation of adiponectin and its receptors. Given the metabolic benefits of RIM, the development of new nonbrain-penetrating CB1R antagonists may provide similar effects while preventing the undesirable central nervous system effects of RIM.
